Guggenheim initiated coverage of ArriVent Biopharma (AVBP) with a Buy rating and $45 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma, Inc.: Promising Clinical Trials and Market Potential Reinforce Buy Rating
- ArriVent BioPharma Reports 2024 Financial Results and Progress
- Buy Rating for ArriVent BioPharma: Promising Clinical Developments and Strategic Progress in NSCLC Treatment
- ArriVent Biopharma sees cash runway into 2026
- ArriVent Biopharma reports FY24 EPS ($2.56), consensus ($2.69)